March 24, 2014
Med BioGene Announces Regulatory Approval of GeneFx® Lung
March 07, 2014
Med BioGene Announces Publication of Data Demonstrating Independent Validation of GeneFx® Lung
January 09, 2014
Med BioGene Announces Dismissal of Litigation With Signal Genetics LLC and Respira Health LLC
November 29, 2013
Med BioGene Reports Financial Results for Q3 2013
November 05, 2013
Med BioGene Provides GeneFx® Lung Regulatory and Commercialization Update
Welcome to Med BioGene
Med BioGene Inc. (MBI: TSX Venture) is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests.
Med BioGene’s lead test under development is GeneFx® Lung (formerly, LungExpress Dx), a proprietary gene expression-based test to improve upon staging for identifying those patients with early-stage non-small-cell lung cancer (NSCLC) who, following surgical removal of their tumor, are at higher and lower risks of mortality. In an initial study of patient specimens from the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial, published in the Journal of Clinical Oncology, patients classified by GeneFx Lung as higher risk benefited from adjuvant chemotherapy, and those classified as lower risk did not benefit and may have experienced a detrimental effect from adjuvant chemotherapy. GeneFx Lung was subsequently validated in predicting patient mortality in four independent studies involving data from tumor specimens totaling 676 untreated early-stage NSCLC patients. GeneFx Lung is expected to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy.
On April 15, 2011, Precision Therapeutics, Inc. and Med BioGene closed their commercialization agreement. The agreement provides to Precision exclusive global rights to develop and commercialize GeneFx Lung.
For more information on Precision Therapeutics, please see www.precisiontherapeutics.com.
© Copyright 2006 - Med BioGene Inc. - Legal Disclaimer